Skip to content

effect of magnesium sulfate on nausea and vomiting after cesarean section

Investigating the effect of magnesium sulfate on nausea and vomiting after cesarean delivery (a clinical trial study)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250526065901N1
Enrollment
60
Registered
2025-06-03
Start date
2025-06-10
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting following spinal cesarean delivery. Delivery by elective caesarean section

Interventions

Intervention 1: Intervention Group: Patients in this group will receive 20 mg/kg of magnesium sulfate diluted in 100 mL of normal saline over 20 minutes prior to spinal anesthesia. This will be follow

Sponsors

Karaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Elective cesarean section RIP2 singleton pregnancy age = 18 years gestational age between 38 and 42 weeks ASA class II BMI less than 30 informed consent obtained no allergy to magnesium sulfate no history of nausea and vomiting during pregnancy."

Exclusion criteria

Exclusion criteria: history of PONV (postoperative nausea and vomiting) history of motion sickness severe nausea and vomiting during pregnancy history of hyperemesis gravidarum severe nausea and vomiting during spinal anesthesia that could not be adequately controlled contraindications to magnesium sulfate administration (including myasthenia gravis, history of hypersensitivity, hypermagnesemia.. presence of liver disease or other end-organ dysfunction twin or complicated pregnancy obesity (BMI > 30 kg/m²) contraindication to regional anesthesia or allergy to local anesthetic history of antidepressant use gastrointestinal disorders any surgery requiring general anesthesia for any reason massive hemorrhage (blood loss > 1 liter) such as placenta previa or placenta accreta duration of cesarean section exceeding 45 minute intraoperative hemodynamic instability such as severe hypotension or significant arrhythmias (e.g., profound bradycardia preeclampsia, eclampsia use of antiemetic medications within the past 24 hours complicated cesarean section for any reason birth of a neonate with an Apgar score < 7, or neonate requiring admission to NICU.

Design outcomes

Primary

MeasureTime frame
Frequency and incidence of nausea and vomit. Timepoint: From the time of anesthesia, every 5 minutes during the operation, and then every 15 minutes for up to 3 hours postoperatively in the recovery room. Method of measurement: Observation, interview, and checklist.;Frequency and incidence of vomit. Timepoint: From the time of anesthesia, every 5 minutes during the operation, and then every 15 minutes for up to 3 hours postoperatively in the recovery room. Method of measurement: Observation, interview, and checklist.

Secondary

MeasureTime frame
Severity of shivering. Timepoint: From the time of anesthesia, every 5 minutes during the operation, and then every 15 minutes for up to 3 hours postoperatively in the recovery room. Method of measurement: Through observation and interview based on the Bedside Shivering Assessment Scale (BSAS).;Postoperative pain. Timepoint: The patient's first complaint of pain following spinal anesthesia. Method of measurement: Through observation and interview based on Visual Analogue Scale (VAS).;Vital signs including blood pressure, heart rate, and oxygen saturation. Timepoint: From the time of anesthesia, every 5 minutes during the operation, and then every 15 minutes for up to 3 hours postoperatively in the recovery room. Method of measurement: Monitoring device including a blood pressure monitor and pulse oximeter.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra mohammadi

Karaj University of Medical Sciences

ghazal.zm1999@gmail.com0098 26 4955535

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026